• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease.

作者信息

Shustov S B

机构信息

Faculty of Endocrinology, Military Medical Academy, St Petersburg, Russia.

出版信息

Curr Med Res Opin. 1997;13(10):573-82. doi: 10.1185/03007999709113331.

DOI:10.1185/03007999709113331
PMID:9327192
Abstract

One hundred and seven adult outpatients with Leriche stage II peripheral occlusive arterial disease took part in this open, controlled trial. Patients were randomly treated over a six-month period either with sulodexide capsules containing 250 lipoproteinlipase releasing units (LRU, two capsules twice daily for 176 days on average: 56 patients), or with pentoxifylline 400 mg tablets (one tablet three times a day for 180 days on average: 51 patients). The incidences of diabetes, hyperlipoproteinaemias, smoking habit and other risk factors were the same in the two groups. The drugs' efficacies were evaluated by monitoring, at the start of treatment and every month during it, the Winsor Index and the walking distance, both prior to (initial claudication distance-IDC) and after (absolute claudication distance-ACD) the symptom's onset. Compliance with treatment and occurrence of adverse events were constantly monitored; systemic tolerability was evaluated through the use of routine haematological and haematochemical tests. Both treatments brought about a progressive increase in the claudication-free walking distance, statistically significant versus baseline from the second month (ACD, sulodexide group) and third month (ACD and ICD, pentoxifilline and sulodexide groups). At the end of treatment, the absolute increase of ACD was significantly greater in sulodexide-treated patients (p < 0.01) with respect to the pentoxifylline-treated group. In both groups the Doppler test evidenced a good improvement in local arterial haemodynamics. In the sulodexide group, 3.6% of patients developed nausea, dyspepsia and other minor gastrointestinal phenomena. In the pentoxifylline group 17.6% of patients complained of gastroenteric disorders (nausea, vomiting, dyspepsia), or of headache and dizziness. In one patient of this latter group insomnia was also present. Systemic tolerance of both drugs was consistently good.

摘要

相似文献

1
Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease.
Curr Med Res Opin. 1997;13(10):573-82. doi: 10.1185/03007999709113331.
2
Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease.
J Int Med Res. 1996 Sep-Oct;24(5):389-406. doi: 10.1177/030006059602400501.
3
A randomized trial of iloprost in patients with intermittent claudication.伊洛前列素治疗间歇性跛行患者的随机试验。
Vasc Med. 2008 Feb;13(1):5-13. doi: 10.1177/1358863X07084910.
4
Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
J Med. 1988;19(2):89-107.
5
Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
Circulation. 1994 Aug;90(2):818-22. doi: 10.1161/01.cir.90.2.818.
6
Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline.
Angiology. 1989 Jul;40(7):639-49. doi: 10.1177/000331978904000706.
7
[Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].前列环素与己酮可可碱治疗下肢周围动脉不可手术的闭塞症患者
Srp Arh Celok Lek. 1999 Jul-Aug;127(7-8):249-53.
8
Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.外周动脉闭塞性疾病II期患者的步行训练与药物治疗。综述。
Int Angiol. 1992 Jul-Sep;11(3):204-10.
9
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.西洛他唑对周围血管疾病所致间歇性跛行患者步行距离的影响。
J Vasc Surg. 1998 Feb;27(2):267-74; discussion 274-5. doi: 10.1016/s0741-5214(98)70357-x.
10
A comparison of cilostazol and pentoxifylline for treating intermittent claudication.西洛他唑与己酮可可碱治疗间歇性跛行的比较。
Am J Med. 2000 Nov;109(7):523-30. doi: 10.1016/s0002-9343(00)00569-6.

引用本文的文献

1
Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis.舒洛地特治疗糖尿病相关并发症:系统评价和荟萃分析。
Adv Ther. 2021 Mar;38(3):1483-1513. doi: 10.1007/s12325-021-01620-1. Epub 2021 Jan 27.
2
Pentoxifylline for intermittent claudication.己酮可可碱用于间歇性跛行
Cochrane Database Syst Rev. 2020 Oct 16;10(10):CD005262. doi: 10.1002/14651858.CD005262.pub4.
3
Sulodexide improves pain-free walking distance in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis.
舒洛地昔改善下肢外周动脉疾病患者无痛行走距离:一项系统评价与荟萃分析。
JRSM Cardiovasc Dis. 2020 Feb 14;9:2048004020907002. doi: 10.1177/2048004020907002. eCollection 2020 Jan-Dec.
4
Pentoxifylline for intermittent claudication.己酮可可碱用于间歇性跛行
Cochrane Database Syst Rev. 2015 Sep 29;9(9):CD005262. doi: 10.1002/14651858.CD005262.pub3.
5
Development and use of sulodexide in vascular diseases: implications for treatment.舒洛地昔在血管疾病中的研发与应用:对治疗的启示
Drug Des Devel Ther. 2013 Dec 24;8:49-65. doi: 10.2147/DDDT.S6762.
6
Use of sulodexide in patients with peripheral vascular disease.舒洛地昔在周围血管疾病患者中的应用。
J Blood Med. 2010;1:105-15. doi: 10.2147/JBM.S10558. Epub 2010 Jun 15.
7
Lipid-lowering for peripheral arterial disease of the lower limb.下肢外周动脉疾病的降脂治疗
Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD000123. doi: 10.1002/14651858.CD000123.pub2.